Acorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research note issued on Saturday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

Acorda Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $24.20. The stock has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. The company has a debt-to-equity ratio of 3.07, a quick ratio of 0.26 and a current ratio of 0.33. The company has a 50-day moving average of $11.75 and a two-hundred day moving average of $12.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACOR. Deutsche Bank AG acquired a new position in shares of Acorda Therapeutics during the 4th quarter worth about $26,000. Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the second quarter valued at approximately $28,000. Geode Capital Management LLC raised its holdings in Acorda Therapeutics by 44.8% during the fourth quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 20,948 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Acorda Therapeutics during the 2nd quarter worth approximately $68,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Acorda Therapeutics by 1,759.1% in the 1st quarter. Susquehanna International Group LLP now owns 218,830 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 207,059 shares in the last quarter. Institutional investors and hedge funds own 12.71% of the company’s stock.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.